OA12787A - Virus-like particles of human papillomavirus. - Google Patents

Virus-like particles of human papillomavirus. Download PDF

Info

Publication number
OA12787A
OA12787A OA1200400239A OA1200400239A OA12787A OA 12787 A OA12787 A OA 12787A OA 1200400239 A OA1200400239 A OA 1200400239A OA 1200400239 A OA1200400239 A OA 1200400239A OA 12787 A OA12787 A OA 12787A
Authority
OA
OAPI
Prior art keywords
hpv
vlps
vaccine
protein
vaccine composition
Prior art date
Application number
OA1200400239A
Other languages
English (en)
Inventor
Wettendorff Martine Ann Cecile
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of OA12787A publication Critical patent/OA12787A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
OA1200400239A 2002-03-18 2003-03-17 Virus-like particles of human papillomavirus. OA12787A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0206360.0A GB0206360D0 (en) 2002-03-18 2002-03-18 Viral antigens

Publications (1)

Publication Number Publication Date
OA12787A true OA12787A (en) 2006-07-10

Family

ID=9933201

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200400239A OA12787A (en) 2002-03-18 2003-03-17 Virus-like particles of human papillomavirus.

Country Status (25)

Country Link
US (3) US7217419B2 (es)
EP (2) EP2044953A1 (es)
JP (2) JP2005524674A (es)
KR (2) KR20050002868A (es)
CN (1) CN100528226C (es)
AP (1) AP1872A (es)
AR (1) AR039005A1 (es)
AU (1) AU2003218787B2 (es)
BR (1) BR0308444A (es)
CA (1) CA2479304C (es)
EA (1) EA011477B1 (es)
EC (1) ECSP045300A (es)
GB (1) GB0206360D0 (es)
IL (2) IL163814A0 (es)
IS (1) IS7426A (es)
MX (1) MXPA04009060A (es)
MY (1) MY139031A (es)
NO (1) NO20044326L (es)
NZ (1) NZ535085A (es)
OA (1) OA12787A (es)
PL (1) PL212981B1 (es)
TW (1) TW200400046A (es)
UA (1) UA85536C2 (es)
WO (1) WO2003077942A2 (es)
ZA (1) ZA200407029B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8956621B2 (en) * 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US8791237B2 (en) * 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
EP2266604A3 (en) * 1998-10-16 2011-05-11 GlaxoSmithKline Biologicals S.A. Adjuvant systems and vaccines
US8771702B2 (en) * 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
CN100506999C (zh) * 2003-03-24 2009-07-01 麦克公司 Hpv31l1在酵母中的优化表达
MY140664A (en) 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
US20080160040A1 (en) * 2004-04-15 2008-07-03 Ghim Shin-Je Plant-produced compositions for treating papillomavirus infection and related methods
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
MXPA06014515A (es) * 2004-06-16 2007-03-23 Glaxosmithkline Biolog Sa Vacuna contra vph16 y vph18 y al menos otro tipo de vph seleccionado de vph 31, 45 o 52.
GB0413510D0 (en) * 2004-06-16 2004-07-21 Glaxosmithkline Biolog Sa Vaccine
US8399610B2 (en) * 2004-08-05 2013-03-19 University College Cardiff Consultants Limited HPV vaccine comprising peptides from host cell proteins
GB0417430D0 (en) * 2004-08-05 2004-09-08 Uc3 A novel HPV vaccine comprising peptides from host cell proteins
EP1853307B1 (en) 2005-02-01 2016-12-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, the Department of Health and Human Services, Papillomavirus L2 N-terminal peptides for the induction of broadly cross-neutralizing antibodies
EP1877087B1 (en) 2005-04-15 2013-02-20 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
CA2606092A1 (en) * 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
MX2007013475A (es) * 2005-04-26 2008-04-02 Glaxosmithkline Biolog Sa Vacuna.
CN1328287C (zh) * 2005-12-29 2007-07-25 西安交通大学 Hpv16 l1蛋白模拟肽及其用于制备hpv16诊断试剂和疫苗的用途
KR100904844B1 (ko) * 2006-08-28 2009-06-25 성균관대학교산학협력단 인유두종 바이러스（ｈｐｖ）유전자를 포함하는자궁경부암의 치료 또는 예방용 ｄｎａ 백신
EP2601969B1 (en) 2006-09-29 2016-03-30 Takeda Vaccines, Inc. Norovirus vaccine formulations
WO2008140474A1 (en) * 2006-10-26 2008-11-20 Johns Hopkins University Recombinant adenovirus vaccines
WO2008115631A2 (en) * 2007-02-08 2008-09-25 University Of Louisville Research Foundation, Inc. Plant-produced compositions for treating papillomavirus infection and related methods
EP2129394B1 (en) * 2007-03-09 2012-06-20 Merck Sharp & Dohme Corp. Papillomavirus vaccine compositions
DK2154147T3 (en) 2007-04-29 2015-12-07 Beijing Wantai Biological Pharmacy Entpr Co Ltd Truncated L1 protein of human papillomavirus 16
WO2008134935A1 (fr) * 2007-04-29 2008-11-13 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Protéines 18 l1 de type papillomavirus humain tronqué
WO2008145021A1 (en) * 2007-05-29 2008-12-04 Xiamen University A truncated l1 protein of human papillomavirus 6
US8088392B2 (en) * 2007-06-18 2012-01-03 Yunxu Cao Capsid proteins and uses therefore
CA2691091C (en) * 2007-06-18 2013-07-30 Shanghai Zerun-Ankegens Biopharmaceutical Co., Ltd Fusion protein, macromolecule assembled from the fusion protein, and its use in the prevention or treatment of human papillomavirus related diseases
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
JP2010539192A (ja) 2007-09-18 2010-12-16 リゴサイト ファーマスーティカルズ，インコーポレイテッド ノロウイルスに対して防御免疫応答を付与する方法
US8100843B2 (en) * 2009-03-24 2012-01-24 GM Global Technology Operations LLC Shape memory polymer medical cast
CN102497880A (zh) * 2009-06-25 2012-06-13 葛兰素史密丝克莱恩生物有限公司 新的人乳头状瘤病毒(hpv)蛋白构建体及其在预防hpv疾病中的用途
CN102178944A (zh) * 2010-09-17 2011-09-14 大连雅立峰生物制药有限公司 人乳头瘤病毒16和18型l1蛋白在昆虫细胞中的表达及应用
PL3299030T3 (pl) 2011-07-11 2022-12-05 Takeda Vaccines, Inc. Pozajelitowe preparaty szczepionek przeciw norowirusowi
CN102552897B (zh) * 2012-01-18 2013-10-30 广东华南联合疫苗开发院有限公司 一种宫颈癌预防性vlp疫苗
KR101559622B1 (ko) * 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
CN104211782B (zh) * 2013-06-04 2017-11-17 厦门大学 截短的人乳头瘤病毒45型l1蛋白
US10799574B2 (en) * 2014-10-24 2020-10-13 Hpvvax. Llc Method and composition for treating cancer or skin lesion using a vaccine
WO2016065281A1 (en) * 2014-10-24 2016-04-28 Tim Ioannides Cancer and skin lesion treatment
CA3015519A1 (en) * 2016-02-27 2017-08-31 Hpvvax, Llc Method and composition for treating cancer or skin lesion using a vaccine

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9113809D0 (en) 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
AU651727B2 (en) 1991-07-19 1994-07-28 Csl Limited Papilloma virus vaccine
DE122007000098I1 (de) 1992-06-25 2008-03-27 Papillomavirus vakzine
US5618536A (en) 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
PT1618888E (pt) 1993-03-09 2011-04-08 Univ Rochester Produção de proteína da cápside de vírus de papiloma humano e partículas semelhantes a vírus
WO1994021292A1 (en) 1993-03-23 1994-09-29 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
CA2189882C (en) * 1994-05-16 2005-09-20 Kathrin U. Jansen Papillomavirus vaccines
CA2202090C (en) * 1994-10-07 2012-04-17 Lutz Gissmann Papilloma virus-like particles, fusion proteins as well as processes for their production
AR004464A1 (es) 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
JP3693449B2 (ja) 1996-04-05 2005-09-07 三菱製紙株式会社 抗菌防黴剤およびそれを含有する繊維状物質
PL336715A1 (en) 1997-04-08 2000-07-03 Merck & Co Inc Stabilised formulation of human papilloma virus
ATE333501T1 (de) 1997-09-05 2006-08-15 Medimmune Inc Methode zur in vitro auseinander- und wiederzusammensetzung von papillomavirus virus- ähnlichen tielchen (vlps)
GB9720585D0 (en) 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
HUP0101047A3 (en) 1998-03-09 2004-10-28 Smithkline Beecham Biolog Combined vaccine compositions
GB9806666D0 (en) 1998-03-27 1998-05-27 Stanley Margaret Antigen preparation and use
WO2000009699A2 (en) 1998-08-14 2000-02-24 Chiron Corporation Method for producing yeast expressed hpv types 6 and 16 capsid proteins
SK2232001A3 (en) * 1998-08-14 2001-08-06 Merck & Co Inc Process for purifying human papillomavirus virus-like particles
EP2266604A3 (en) 1998-10-16 2011-05-11 GlaxoSmithKline Biologicals S.A. Adjuvant systems and vaccines
EP1150712B1 (en) 1999-02-05 2008-11-05 Merck & Co., Inc. Human papilloma virus vaccine formulations
US6245568B1 (en) * 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
GB9921147D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
OA12168A (en) 2000-01-31 2006-05-08 Smithkline Beecham Biolog Vaccine for the prophylactic or therapeutic immunization against HIV.
US6908613B2 (en) 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
US7279306B2 (en) * 2000-07-06 2007-10-09 Georgetown University Stable (fixed) forms of viral capsid proteins, and viral capsid protein fusions, preferably papillomavirus L1 proteins, and uses thereof
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
US20040121465A1 (en) * 2002-02-14 2004-06-24 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
DE60336581D1 (de) 2002-12-20 2011-05-12 Glaxosmithkline Biolog Sa Verwendung von HPV16 und HPV18 VLPs als Vakzine gegen eine oder mehrere onkogene HPV des Typus 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
MY140664A (en) 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast

Also Published As

Publication number Publication date
EA200401064A1 (ru) 2005-04-28
CN100528226C (zh) 2009-08-19
WO2003077942A3 (en) 2003-12-24
IL163814A0 (en) 2005-12-18
AP1872A (en) 2008-08-04
IL163814A (en) 2009-07-20
MY139031A (en) 2009-08-28
EP1492562A2 (en) 2005-01-05
US7815915B2 (en) 2010-10-19
JP2010090158A (ja) 2010-04-22
AP2004003136A0 (en) 2004-09-30
ZA200407029B (en) 2005-11-30
IS7426A (is) 2004-09-15
US20080279890A1 (en) 2008-11-13
AU2003218787A1 (en) 2003-09-29
CA2479304A1 (en) 2003-09-25
US7217419B2 (en) 2007-05-15
MXPA04009060A (es) 2005-01-25
US20050175632A1 (en) 2005-08-11
PL372937A1 (en) 2005-08-08
CA2479304C (en) 2013-10-08
ECSP045300A (es) 2005-01-03
EA011477B1 (ru) 2009-04-28
NO20044326L (no) 2004-10-14
GB0206360D0 (en) 2002-05-01
AR039005A1 (es) 2005-02-02
UA85536C2 (en) 2009-02-10
NZ535085A (en) 2006-08-31
BR0308444A (pt) 2005-01-18
CN1642571A (zh) 2005-07-20
KR20110009249A (ko) 2011-01-27
JP2005524674A (ja) 2005-08-18
KR20050002868A (ko) 2005-01-10
PL212981B1 (pl) 2012-12-31
WO2003077942A2 (en) 2003-09-25
US7416846B2 (en) 2008-08-26
TW200400046A (en) 2004-01-01
EP2044953A1 (en) 2009-04-08
AU2003218787B2 (en) 2006-04-06
NO20044326D0 (no) 2004-10-12
US20070224218A1 (en) 2007-09-27

Similar Documents

Publication Publication Date Title
OA12787A (en) Virus-like particles of human papillomavirus.
US7205125B2 (en) Mixed Virus-like particles
Jagu et al. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines
US20120087937A1 (en) Novel compositions
EP2589604B1 (en) Truncated l1 protein of human papillomavirus type 52
WO2008145021A1 (en) A truncated l1 protein of human papillomavirus 6
US20200230226A1 (en) Viral antigens
WO2004052395A1 (en) L2-peptide of the human papillomavirus associated with virus-like particles
KR20050050115A (ko) 유두종바이러스의 2종 이상의 비구조적 초기 단백질을암호화하는 ｄｎａ 백신
MXPA00009282A (es) Medicamento para la prevencion o tratamiento de tumores especificos del virus de papiloma.
CN114681602A (zh) 一种双价人乳头瘤病毒疫苗
WO1998010790A1 (en) Papillomavirus vaccine formulation